Chestnut Hill, MA, United States of America

Paul M Ridker

USPTO Granted Patents = 10 (Patent Applications = 8)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 1.9

ph-index = 4

Forward Citations = 151(Granted Patents)

Company Filing History:

10 out of 1,371

The Brigham and Women's Hospital, Inc.

where one patent can have more than one assignee

Years Active: 2000-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11697850 - Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment (2023-07-11),

2. 11435363 - Relevance of achieved levels of markers of systemic inflammation following treatment (2022-09-06),

3. 10550433 - Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment (2020-02-04),

4. 9164104 - Relevance of achieved levels of markers of systemic inflammation following treatment (2015-10-20),

5. 8101363 - Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes (2012-01-24),

6. 7964614 - Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease (2011-06-21),

7. 7943317 - Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment (2011-05-17),

8. 7189518 - Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases (2007-03-13),

9. 7030152 - Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease (2006-04-18),

10. 6040147 - Systemic inflammatory markers as diagnostic tools in the prevention of (2000-03-21),

Title: Paul M Ridker: Innovator in Cardiovascular Research

Introduction

Paul M Ridker is a prominent inventor based in Chestnut Hill, MA (US), known for his significant contributions to cardiovascular research. He holds a total of 10 patents, reflecting his innovative approach to understanding and treating cardiovascular diseases.

Latest Patents

One of Ridker's latest patents is focused on polymorphism in the Apo(a) gene, which predicts responsiveness to acetylsalicylic acid treatment. This invention relates to nucleotide polymorphisms in the human Apo(a) gene and aims to identify whether a human subject will respond to treatment with acetylsalicylic acid. Another notable patent involves the relevance of achieved levels of markers of systemic inflammation following treatment. This invention utilizes markers of systemic inflammation to determine if an individual undergoing treatment with a cardiovascular agent will benefit from continued treatment. It also describes how these markers can evaluate treatment efficacy and assist physicians in deciding on the best course of action for individuals at risk of future cardiovascular events.

Career Highlights

Throughout his career, Ridker has worked with esteemed institutions such as The Brigham and Women's Hospital, Inc. and Celera Corporation. His work has significantly advanced the understanding of cardiovascular health and treatment options.

Collaborations

Ridker has collaborated with notable colleagues, including Charles H Hennekens and Daniel Chasman, further enhancing the impact of his research in the field of cardiovascular medicine.

Conclusion

Paul M Ridker's innovative contributions to cardiovascular research through his patents and collaborations have made a lasting impact on the medical community. His work continues to influence the treatment and understanding of cardiovascular diseases.

This text is generated by artificial intelligence and may not be accurate.